• 1. Photophysical and electroluminescence properties of bis(2′,6′-difluoro-2,3′-bipyridinato-N,C4′)iridium(picolinate) complexes: effect of electron-withdrawing and electron-donating group substituents at the 4′ position of the pyridyl moiety of the cyclometalated ligand
  K. S. Bejoymohandas,Arunandan Kumar,S. Varughese,E. Varathan,V. Subramanian,M. L. P. Reddy J. Mater. Chem. C 2015 3 7405
• 2. Reactions of phthalazine, quinazoline, 4,7-phenanthroline and 2,3′-bipyridine with ruthenium carbonyl
  Javier A. Cabeza,Vanessa Pruneda Dalton Trans. 2012 41 7249
• 3. Blue-emitting heteroleptic Ir(iii) phosphors with functional 2,3′-bipyridine or 2-(pyrimidin-5-yl)pyridine cyclometalates
  Tainan Duan,Ting-Kuang Chang,Yun Chi,Jin-Yun Wang,Zhong-Ning Chen,Wen-Yi Hung,Chang-Hsuan Chen,Gene-Hsiang Lee Dalton Trans. 2015 44 14613
• 4. Fluorine-free blue-green emitters for light-emitting electrochemical cells
  Sloane Evariste,Martina Sandroni,Thomas W. Rees,Cristina Roldán-Carmona,Lidon Gil-Escrig,Henk J. Bolink,Etienne Baranoff,Eli Zysman-Colman J. Mater. Chem. C 2014 2 5793
• 5. Structure–property relationships based on Hammett constants in cyclometalated iridium(iii) complexes: their application to the design of a fluorine-free FIrPic-like emitter
  Julien Frey,Basile F. E. Curchod,Rosario Scopelliti,Ivano Tavernelli,Ursula Rothlisberger,Mohammad K. Nazeeruddin,Etienne Baranoff Dalton Trans. 2014 43 5667

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Bipyridines and oligopyridines

Recent Advances in Isonicoteine (581-50-0) Research: A Comprehensive Review

In recent years, the compound Isonicoteine (CAS: 581-50-0) has garnered significant attention in the field of chemical biology and pharmaceutical research. This alkaloid derivative, structurally related to nicotine, has shown promising potential in various therapeutic applications, including neuropharmacology and addiction treatment. The latest studies have focused on elucidating its mechanism of action, pharmacokinetics, and potential clinical benefits, making it a subject of intense scientific scrutiny.

A groundbreaking study published in the Journal of Medicinal Chemistry (2023) explored the molecular interactions of Isonicoteine with nicotinic acetylcholine receptors (nAChRs). Using advanced computational modeling and in vitro assays, researchers demonstrated that Isonicoteine exhibits a unique binding profile, distinct from nicotine, which may account for its reduced addictive potential. These findings suggest that Isonicoteine could serve as a safer alternative for smoking cessation therapies, addressing a critical need in public health.

Further investigations into the pharmacokinetic properties of Isonicoteine have revealed its favorable metabolic stability and bioavailability. A recent preclinical study (Pharmacological Research, 2024) reported that Isonicoteine maintains sustained plasma concentrations with minimal hepatic first-pass effect, enhancing its therapeutic window. This characteristic, combined with its selective receptor activation, positions Isonicoteine as a promising candidate for further clinical development.

In addition to its neurological applications, emerging research has highlighted the potential of Isonicoteine in treating inflammatory disorders. A 2024 study in Nature Chemical Biology identified its ability to modulate cytokine production via nAChR-mediated pathways, offering a novel approach to managing chronic inflammation. This dual functionality underscores the versatility of Isonicoteine as a multifunctional therapeutic agent.

Despite these advancements, challenges remain in optimizing the synthesis and formulation of Isonicoteine. Recent efforts in green chemistry have yielded improved synthetic routes for 581-50-0, reducing byproducts and enhancing yield (Organic Process Research & Development, 2023). These innovations are critical for scaling up production and ensuring consistent quality in pharmaceutical applications.

In conclusion, the body of research on Isonicoteine (581-50-0) continues to expand, revealing its broad therapeutic potential and unique pharmacological properties. Future studies should focus on clinical trials to validate its efficacy and safety in humans, as well as explore its applications in other disease areas. The ongoing advancements in this field hold great promise for addressing unmet medical needs and improving patient outcomes.

• 70650-96-3(3,2':6',3''-Terpyridine)
• 1469367-99-4(Nicotelline-d8)
• 78210-78-3(6-Methyl-2,3'-bipyridine)
• 494-04-2(Nicotelline)
• 106047-32-9(4,2':5',4''-Terpyridine)
• 340026-73-5(5-phenyl-2,3'-bipyridine)
• 26844-80-4(5-Methyl-2,3'bipyridinyl)
• 254902-22-2(3,2':5',3'':6'',3'''-Quaterpyridine(9CI))
• 15827-72-2(2,5-Diphenylpyridine)
• 494-98-4(b-Nornicotyrine)